GenSpera Inc. (GenSpera) is a development-stage company. The Company is a pharmaceutical company focused on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder and kidney cancer. Its operations are based in San Antonio, Texas. As of January 6, 2012, the Company had not generated sales revenues. Its Prodrug Therapies include cancer chemotherapy involves treating patients with cytotoxic drugs (compounds or agents that are toxic to cells). The Company owns claims that cover 12ADT as a composition of matter. 12ADT is a chemically modified form of thapsigargin, a cytotoxin that kills fast-, slow- and non-dividing cells. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301.